Get the latest news and updates
Dr. Ostertag directed Poseida’s spin out from Transposagen in February 2015 and has served as our chief executive officer and as a member of our board of directors since May 2015. From October 2003 to July 2015, Dr. Ostertag founded and served as the chief executive officer and president of Transposagen Biopharmaceuticals, Inc., a biotechnology company that commercializes early gene editing technology in the research reagent space. Dr. Ostertag previously co-founded and served as chief executive officer and president of Vindico NanoBioTechnology, Inc., a biotechnology company engaged in the discovery, development, and commercialization of human therapeutics that are based on a nanometer-scale particulate technology. Dr. Ostertag also co-founded and served as executive vice president of PhenoTech, Inc., a biotechnology company engaged in the discovery, development, and commercialization of reagents for diagnostic use in blood banks.
A Novel Approach To CAR-T Therapy
CART Therapeutics comprised of a high percentage of stem cell memory T cells exhibit unique properties that could potentially solve most of the limitations of early-generation CART products, including significant toxicities, historically poor efficacy against solid tumors, and high costs.
Immunotherapy Showcase: Poseida Therapeutics, Inc.
Poseida is a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell therapeutics for patients with high unmet medical need.